Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criterion:~- AHI \> 20~Exclusion Criteria:~* Any medical condition other than well controlled hypertension.~* Any medication known to influence breathing, sleep/arousal or muscle physiology.~* Claustrophobia.~* Inability to sleep supine.~* Allergy to lidocaine, Oxymetazoline HCl, atomoxetine/oxybutynin.~* Individuals with underlying cardiac disease, such as arrhythmias.~* Individuals taking psychiatric medications, such as atomoxetine, or any of the studied medications for medical care.~* History of seizures~* For women: Pregnancy.~* History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 hours before bedtime
- Combination product of Atomoxetine and Oxybutynin (Type: ACTIVE_COMPARATOR): Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep

Based on this trial design, predict the completion outcome and termination type (if applicable).